<DOC>
	<DOCNO>NCT00002133</DOCNO>
	<brief_summary>To assess efficacy safety itraconazole oral solution HIV-seropositive patient oropharyngeal candidiasis refractory fluconazole .</brief_summary>
	<brief_title>An Open Study Effect Itraconazole Oral Solution Treatment Fluconazole Refractory Oropharyngeal Candidiasis HIV-Positive Subjects .</brief_title>
	<detailed_description>Patients receive itraconazole oral solution twice daily . Per 08/15/94 amendment , patient complete resolution oropharyngeal candidiasis lesion upon completion treatment eligible maintenance treatment protocol FDA 236C . Patients decline maintenance follow 6 week . Patients relapse follow-up re-treated 14-28 day ; lesion clear , patient may enter maintenance protocol .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Oral</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV antibody seropositivity diagnosis AIDS . Confirmed oropharyngeal candidiasis . Failed fluconazole treatment within past 14 day . Life expectancy least 3 month . NO symptoms esophageal candidiasis ( e.g. , dysphagia ) unless endoscopic exam esophagus perform fungal esophagitis present . NO prior disseminate candidiasis . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Underlying clinical condition precludes study completion place patient significant risk . Considered unreliable follow physician 's directive . Concurrent Medication : Excluded : Investigational drug ( approve expand access drug permit ) . Rifampin . Rifabutin . Phenobarbital . Phenytoin . Carbamazepine . Terfenadine . Astemizole . Patients follow prior condition exclude : History hypersensitivity imidazole azole compound . Clinical evidence significant hepatic disease within past 2 month . Prior Medication : Excluded : Investigational drug within 1 month prior study entry ( approve expand access drug permit ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Itraconazole</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Candidiasis , Oral</keyword>
</DOC>